Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma (Q35113661)

6 August 2017

1 reference

title

Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma (English)

1 reference

6 August 2017

1 reference

Liu Yang

1

1 reference

6 August 2017

Ka-yun Ng

series ordinal

2

1 reference

6 August 2017

Kevin O Lillehei

series ordinal

3

1 reference

6 August 2017

publication date

1 March 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

10

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

138-147

1 reference

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Brain tumor survival: results from the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Lymphocytic infiltration in gliomas: evidence of possible host resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Relationship of lymphocyte invasion and survival of brain tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Tumor antigens in astrocytic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma--phase I and II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Human glioma immunobiology in vitro: implications for immunogene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Immunohistological study of mononuclear cell infiltrate in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Immunobiology of primary intracranial tumors. Part 5: Correlation of a lymphocyte index and clinical status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Modulation of T-cell function by gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta 2 inhibits the generation of lymphokine-activated killer (LAK) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Influence of PGE2- and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2-activated lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

[Delayed hypersensitivity reactions in patients bearing malignant brain tumors with human tumor cell lines grown in vitro].

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Interleukin-12-based immunotherapy against rat 9L glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Survival and toxicity of an allogeneic cytokine-secreting fibroblast vaccine in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Current perspectives in immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Effect of irradiation on transforming growth factor-beta secretion by malignant glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Quantification of tumor-specific T lymphocytes with the ELISPOT assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327480301000205

10.1177/107327480301000205

21 January 2018

Identifiers

DOI

0 references

1 reference